Enanta’s Lead HCV Protease Inhibitor Compound ABT-450 Advances into Phase 3 Clinical Trial in a Triple Combination Treatment with Abbott’s NS5A Inhibitor
Enanta Pharmaceuticals Enters into Strategic Collaboration with Novartis to Advance Enanta’s NS5A Inhibitor Candidate for Hepatitis C Virus